Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs

Acromegaly

(2019) Annamaria Colao et al.   Nature Reviews Disease Primers

Systemic complications of acromegaly and the impact of the current treatment landscape: an update

(2018) Mônica R Gadelha et al.   ENDOCRINE REVIEWS

A Consensus Statement on acromegaly therapeutic outcomes

(2018) Shlomo Melmed et al.   Nature Reviews Endocrinology

The role of cumulative growth hormone exposure in determining mortality and morbidity in acromegaly: a single centre study

(2016) Lakshminarayanan Varadhan et al.   Pituitary

Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study

(2015) Donato Iacovazzo et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

The Introduction of the IDS-iSYS Total IGF-1 Assay May Have Far-Reaching Consequences for Diagnosis and Treatment of GH Deficiency

(2015) A. J. Varewijck et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly

(2015) Annamaria Colao et al.   Pituitary

Acromegaly: An Endocrine Society Clinical Practice Guideline

(2014) Laurence Katznelson et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

(2014) A. Colao et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial

(2014) Mônica R Gadelha et al.   Lancet Diabetes & Endocrinology

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 Update

(2013) Laurence Katznelson et al.   Endocrine Practice

Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers

(2013) Robert R. Henry et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations

(2013) Annamaria Colao et al.   Pituitary

Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY

(2012) A. J. van der Lely et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)

(2011) M. Herdman et al.   QUALITY OF LIFE RESEARCH

Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed

(2009) Tirissa J. Reid et al.   CLINICAL ENDOCRINOLOGY

Acromegaly pathogenesis and treatment

(2009) Shlomo Melmed   JOURNAL OF CLINICAL INVESTIGATION

Efficacy of long-term lanreotide treatment in patients with acromegaly

(2009) Yoel Toledano et al.   Pituitary

Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension

(2009) Shlomo Melmed et al.   Pituitary

Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48weeks in patients with acromegaly

(2008) Philippe Chanson et al.   CLINICAL ENDOCRINOLOGY

Octreotide LARvs.surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study

(2008) Annamaria Colao et al.   CLINICAL ENDOCRINOLOGY